Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.56 |
| ▸ | GABRD | O14764 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.56 |
| ▸ | GABRE | P78334 | 1/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.56 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.56 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.56 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10422199 | 0.80 | TSHR (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12647991 | 0.79 | TSHR (0.51) | MAPTTSHRALDH1A1HPGDKDM4E | |
| SCHEMBL10901482 | 0.78 | TSHR (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20806339 | 0.78 | TSHR (0.58) | MAPTTSHRALDH1A1HPGDKDM4E | |
| SCHEMBL27642812 | 0.77 | TTR (0.51) | MAPTTSHRALDH1A1LMNAKDM4E | |
| SCHEMBL6852156 | 0.77 | TSHR (0.53) | MAPTTSHRALDH1A1LMNAHPGD | |
| SCHEMBL4914123 | 0.75 | MAPT (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2268884 | 0.75 | MAPT (0.75) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1560864 | 0.75 | CDC25B (0.54) | MAPTTSHRALDH1A1HPGDKDM4E | |
| SCHEMBL20806387 | 0.74 | TSHR (0.49) | MAPTTSHRALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200551-A1 | Flourene Derivative | ASTELLAS PHARMA INC. (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | ASTELLAS PHARMA INC. (JP) | 2008-07-17 | — | — | US | disclosed |
| US-20080161419-A1 | Prophylactic Antimigraine Agents | ASTELLAS PHARMA INC. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852129-A1 | REMEDY FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1728784-A1 | FLUORENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-06 | — | — | EP | disclosed |
| EP-1716867-A1 | PREVENTIVES FOR MIGRAINE | Astellas Pharma Inc. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161419-A1 | Prophylactic Antimigraine Agents | HTR2B, HTR7, HTR1A | GABRP 676/4885GABRD 877/4885GABRA1 635/4885 |
| US-20080200551-A1 | Flourene Derivative | HTR2B, HTR7, HTR2C | GABRP 1621/4885GABRD 1869/4885GABRA1 849/4885 |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | HTR7, HTR5A, HTR3B | GABRP 179/4885GABRD 667/4885GABRA1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.